​
​

MacroGenics (MGNX) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

MacroGenics Revenue Highlights

Latest Revenue (Y)

$58.75M

Latest Revenue (Q)

$110.71M

Main Segment (Y)

Revenue From Collaborative Agreements

MacroGenics Revenue by Period

MacroGenics Revenue by Year

DateRevenueChange
2023-12-31$58.75M-61.33%
2022-12-31$151.94M100.87%
2021-12-31$75.64M-22.63%
2020-12-31$97.76M57.62%
2019-12-31$62.02M3.17%
2018-12-31$60.12M-61.34%
2017-12-31$155.52M79.62%
2016-12-31$86.58M-14.15%
2015-12-31$100.85M113.38%
2014-12-31$47.26M-16.72%
2013-12-31$56.75M-4.85%
2012-12-31$59.65M26.76%
2011-12-31$47.05M-

MacroGenics generated $58.75M in revenue during NA 2023, up -61.33% compared to the previous quarter, and up 97.72% compared to the same period a year ago.

MacroGenics Revenue by Quarter

DateRevenueChange
2024-09-30$110.71M925.36%
2024-06-30$10.80M18.60%
2024-03-31$9.10M-15.07%
2023-12-31$10.72M3.11%
2023-09-30$10.40M-20.85%
2023-06-30$13.14M-45.75%
2023-03-31$24.21M-65.98%
2022-12-31$71.18M70.55%
2022-09-30$41.73M60.47%
2022-06-30$26.01M143.67%
2022-03-31$10.67M-21.66%
2021-12-31$13.62M-12.54%
2021-09-30$15.58M-48.71%
2021-06-30$30.37M88.98%
2021-03-31$16.07M-68.94%
2020-12-31$51.75M197.13%
2020-09-30$17.41M11.38%
2020-06-30$15.64M20.58%
2020-03-31$12.97M-47.19%
2019-12-31$24.56M36.54%
2019-09-30$17.98M80.07%
2019-06-30$9.99M5.16%
2019-03-31$9.50M-42.27%
2018-12-31$16.45M-20.21%
2018-09-30$20.62M11.13%
2018-06-30$18.55M312.18%
2018-03-31$4.50M-97.08%
2017-12-31$154.31M14240.80%
2017-09-30$1.08M-0.46%
2017-06-30$1.08M-15.41%
2017-03-31$1.28M-86.51%
2016-12-31$9.48M370.51%
2016-09-30$2.01M-97.43%
2016-06-30$78.50M4046.70%
2016-03-31$1.89M-76.85%
2015-12-31$8.18M-44.30%
2015-09-30$14.68M118.60%
2015-06-30$6.72M-90.58%
2015-03-31$71.28M1201.66%
2014-12-31$5.48M-70.21%
2014-09-30$18.38M99.37%
2014-06-30$9.22M-37.36%
2014-03-31$14.72M-1.26%
2013-12-31$14.91M-26.32%
2013-09-30$20.23M64.52%
2013-06-30$12.30M16.04%
2013-03-31$10.60M8.16%
2012-12-31$9.80M-39.07%
2012-09-30$16.08M-

MacroGenics generated $110.71M in revenue during Q3 2024, up 925.36% compared to the previous quarter, and up 842.78% compared to the same period a year ago.

MacroGenics Revenue Breakdown

MacroGenics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21Dec 20Dec 19
Revenue From Government Agreements$1.56M$1.92M$1.80M$7.12M$2.16M
Contract Manufacturing$9.83M$13.99M---
Product$17.94M$16.73M$12.35M--
Revenue From Collaborative Agreements$28.99M$119.30M$63.29M$97.76M$62.02M

MacroGenics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Revenue From Collaborative Agreements (49.71%), Product (30.76%), Contract Manufacturing (16.86%), and Revenue From Government Agreements (2.67%).

Quarterly Revenue by Product

Product/ServiceSep 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
RevenueFromCollaborativeAgreementsMember$101.41M$1.45M$885.00K$6.02M$16.69M$35.67M$16.86M$7.09M$11.99M$27.17M$15.18M$17.41M$15.64M$12.97M$17.98M-----
Contract Manufacturing$4.57M$2.28M$169.00K$4.46M$1.59M$3.62M$8.85M$1.14M$3.99M-----------
Government Contract$566.00K-------------------
Product$4.16M$4.86M$4.69M$4.70M$5.06M$3.49M$4.10M$4.37M$4.67M$3.58M$4.67M$3.59M$3.20M$887.00K------
RevenueFromGovernmentAgreementsMember-$358.00K$345.00K$466.00K$283.00K$547.00K$480.00K$428.00K$85.00K$386.00K$810.00K$838.00K$4.62M$715.00K$757.00K-----
Revenue From Collaborative Agreements------$59.67M$8.96M$51.75M$24.56M----------
Revenue From Government Agreements------$468.00K$523.00K$945.00K$636.00K----------

MacroGenics's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: RevenueFromCollaborativeAgreementsMember (91.60%), Contract Manufacturing (4.13%), Product (3.76%), and Government Contract (0.51%).

MacroGenics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
PTGXProtagonist Therapeutics$60.00M$4.67M
MGNXMacroGenics$58.75M$110.71M
MOLNMolecular Partners$7.04M$2.74M
KZRKezar Life Sciences$7.00M-
IPSCCentury Therapeutics$2.23M$791.00K
CGEMCullinan Oncology--
CCCCC4 Therapeutics--
ANTXAN2 Therapeutics--
PHVSPharvaris--
DAWNDay One Biopharmaceuticals-$20.07M
NGMNGM Biopharmaceuticals-$165.00K
NKTXNkarta--
INZYInozyme Pharma--
SNDXSyndax Pharmaceuticals-$12.50M
PMVPPMV Pharmaceuticals--
MLYSMineralys Therapeutics--
GLUEMonte Rosa Therapeutics-$4.70M
ZNTLZentalis Pharmaceuticals--
EWTXEdgewise Therapeutics--
PEPGPepGen--
TYRATyra Biosciences--

MGNX Revenue FAQ

What is MacroGenics’s yearly revenue?

MacroGenics's yearly revenue for 2023 was $58.75M, representing a decrease of -61.33% compared to 2022. The company's yearly revenue for 2022 was $151.94M, representing an increase of 100.87% compared to 2021. MGNX's yearly revenue for 2021 was $75.64M, representing a decrease of -22.63% compared to 2020.

What is MacroGenics’s quarterly revenue?

MacroGenics's quarterly revenue for Q3 2024 was $110.71M, a 925.36% increase from the previous quarter (Q2 2024), and a 964.81% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $10.8M, a 18.60% increase from the previous quarter (Q1 2024), and a -17.81% decrease year-over-year (Q2 2023). MGNX's quarterly revenue for Q1 2024 was $9.1M, a -15.07% decrease from the previous quarter (Q4 2023), and a -62.40% decrease year-over-year (Q1 2023).

What is MacroGenics’s revenue growth rate?

MacroGenics's revenue growth rate for the last 3 years (2021-2023) was -22.33%, and for the last 5 years (2019-2023) was -5.28%.

What are MacroGenics’s revenue streams?

MacroGenics's revenue streams in c 23 are Revenue From Government Agreements, Contract Manufacturing, Product, and Revenue From Collaborative Agreements. Revenue From Government Agreements generated $1.56M in revenue, accounting 2.67% of the company's total revenue, down -19.08% year-over-year. Contract Manufacturing generated $9.83M in revenue, accounting 16.86% of the company's total revenue, down -29.70% year-over-year. Product generated $17.94M in revenue, accounting 30.76% of the company's total revenue, up 7.25% year-over-year. Revenue From Collaborative Agreements generated $28.99M in revenue, accounting 49.71% of the company's total revenue, down -75.70% year-over-year.

What is MacroGenics’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of MacroGenics was Revenue From Collaborative Agreements. This segment made a revenue of $28.99M, representing 49.71% of the company's total revenue.